Use of genome-wide association studies for drug repositioning.
paper
Cited
Public
Unavailable
- Authors
- Sanseau, Philippe; Agarwal, Pankaj; Barnes, Michael R; Pastinen, Tomi; Richards, J Brent; Cardon, Lon R; Mooser, Vincent
- Year
- 2012
- Journal
- Nature biotechnology
- PMID
- 22491277
- DOI
- 10.1038/nbt.2151
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| A genetics-guided integrative framework for drug repurposing: identifying antihypertensive drugs for type 2 diabetes. | Zhong X et al. | β | 2026 | β |
| Drug repurposing: a promising drug discovery strategy for the treatment of emerging epidemic infectious disease. | Zhang S et al. | β | 2026 | β |
| Evaluation of LG's anticancer actiΜviΜty on human gastric cancer cell line HGC-27 via molecular docking and gene expression analysis. | Ciraci E et al. | β | 2026 | β |
| Genetic interactions between bioactive ingredients in traditional Chinese medicine and major depressive disorder, bipolar disorder, and schizophrenia. | Xu Y et al. | β | 2026 | β |
| A Deep Subgrouping Framework for Precision Drug Repurposing via Emulating Clinical Trials on Real-world Patient Data. | Lee S et al. | β | 2025 | β |
| Atlas of the plasma proteome in health and disease in 53,026 adults. | Deng YT et al. | β | 2025 | β |
| Drug Repurposing: Insights into Current Advances and Future Applications. | Bhatia T et al. | β | 2025 | β |
| Genome-Wide Association Study of Cognitive Function in Population-Based Cohorts in Japan: The Tohoku Medical Megabank Brain Magnetic Resonance Imaging Study. | Shinoda G et al. | β | 2025 | β |
| Innovative horizons: harnessing drug repositioning for targeted therapeutics in colorectal cancer. | Tarin M et al. | β | 2025 | β |
| Linking Genome-Wide Association Studies to Pharmacological Treatments for Psychiatric Disorders. | Arnatkeviciute A et al. | β | 2025 | β |
| Shared molecular, cellular, and environmental hallmarks in cardiovascular disease and cancer: Any place for drug repurposing? | Avolio E et al. | β | 2025 | β |
| The effect of fampridine on working memory: a randomized controlled trial based on a genome-guided repurposing approach. | Papassotiropoulos A et al. | β | 2025 | β |
| The future of metronomic chemotherapy: experimental and computational approaches of drug repurposing. | Abdelrady YA et al. | β | 2025 | β |
| Drug repurposing for metabolic disorders: Scientific, technological and economic issues. | Bui NL et al. | β | 2024 | β |
| Exploring the potential of drug repurposing for treating depression. | Verma C et al. | β | 2024 | β |
| Genetic and Epigenetic Landscape for Drug Development in Polycystic Ovary Syndrome. | Chen Y et al. | β | 2024 | β |
| Genomic strategies for drug repurposing. | Dave K et al. | β | 2024 | β |
| Navigating the Intersection of Technology and Depression Precision Medicine. | Irmak-Yazicioglu MB et al. | β | 2024 | β |
| Novel strategies for drug repurposing. | Takundwa MM et al. | β | 2024 | β |
| Repurposing of biologics and biopharmaceuticals. | Israr J et al. | β | 2024 | β |
| The importance of functional genomics studies in precision rheumatology. | Piedade AP et al. | β | 2024 | β |
| A genetically supported drug repurposing pipeline for diabetes treatment using electronic health records. | Shuey MM et al. | β | 2023 | β |
| A Review on Artificial Intelligence Approaches and Rational Approaches in Drug Discovery. | Srivathsa AV et al. | β | 2023 | β |
| Current trends and future prospects of drug repositioning in gastrointestinal oncology. | Fatemi N et al. | β | 2023 | β |
| Drug repurposing-a promising approach for patients with angina but non-obstructive coronary artery disease (ANOCA). | McChord J et al. | β | 2023 | β |
| Drug Repurposing in Non-Small Cell Lung Carcinoma: Old Solutions for New Problems. | Doumat G et al. | β | 2023 | β |
| Examining the shared etiology of psychopathology with genome-wide association studies. | Mallard TT et al. | β | 2023 | β |
| Genetic and Gene Expression Resources for Osteoporosis and Bone Biology Research. | Kaya S et al. | β | 2023 | β |
| Germline mechanisms of immunotherapy toxicities in the era of genome-wide association studies. | Gusev A | β | 2023 | β |
| Harnessing the Power of Electronic Health Records and Genomics for Drug Discovery. | Krebs K et al. | β | 2023 | β |
| Myocardial Recovery in Recent Onset Dilated Cardiomyopathy: Role of <i>CDCP1</i> and Cardiac Fibrosis. | Liu D et al. | β | 2023 | β |
| New drug-like small molecule antagonizes phosphatidylinositol (3,4,5)-trisphosphate (PIP3) in patients with conotruncal heart defects. | Fayez AG et al. | β | 2023 | β |
| New "drugs and targets" in the GWAS era of bipolar disorder. | Qi HX et al. | β | 2023 | β |
| Bibliometric and Visual Analysis on Metabolomics in Coronary Artery Disease Research. | Yu N et al. | β | 2022 | β |
| Combinational Drug Repurposing from Genetic Networks Applied to Alzheimer's Disease. | Nabirotchkin S et al. | β | 2022 | β |
| Considerations and challenges for sex-aware drug repurposing. | Fisher JL et al. | β | 2022 | β |
| Deep learning identifies explainable reasoning paths of mechanism of action for drug repurposing from multilayer biological network. | Yang J et al. | β | 2022 | β |
| Drug repurposing: a systematic review on root causes, barriers and facilitators. | Krishnamurthy N et al. | β | 2022 | β |
| Exploration of Target Spaces in the Human Genome for Protein and Peptide Drugs. | Liu Z et al. | β | 2022 | β |
| GEFA: Early Fusion Approach in Drug-Target Affinity Prediction. | Nguyen TM et al. | β | 2022 | β |
| Genetics of common cerebral small vessel disease. | Bordes C et al. | β | 2022 | β |
| Identification of Potential Treatments for Acute Lymphoblastic Leukemia through Integrated Genomic Network Analysis. | Zazuli Z et al. | β | 2022 | β |
| Integrating gene expression and clinical data to identify drug repurposing candidates for hyperlipidemia and hypertension. | Wu P et al. | β | 2022 | β |
| KGML-xDTD: a knowledge graph-based machine learning framework for drug treatment prediction and mechanism description. | Ma C et al. | β | 2022 | β |
| Learning multi-scale heterogenous network topologies and various pairwise attributes for drug-disease association prediction. | Zhang H et al. | β | 2022 | β |
| Linking GWAS to pharmacological treatments for psychiatric disorders | Arnatkeviciute A et al. | β | 2022 | β |
| Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing. | Bahmad HF et al. | β | 2022 | β |
| Pharmacogenomics for the efficacy and side effects of antihistamines. | Li L et al. | β | 2022 | β |
| Pharmacometabolomics-Based Translational Biomarkers: How to Navigate the Data Ocean. | Bafiti V et al. | β | 2022 | β |
| Repurposing drugs to treat cardiovascular disease in the era of precision medicine. | Abdelsayed M et al. | β | 2022 | β |
| StarGazer: A Hybrid Intelligence Platform for Drug Target Prioritization and Digital Drug Repositioning Using Streamlit. | Lee C et al. | β | 2022 | β |
| Target Discovery for Drug Development Using Mendelian Randomization. | Evans DS | β | 2022 | β |
| The druggable schizophrenia genome: from repurposing opportunities to unexplored drug targets. | Lago SG et al. | β | 2022 | β |
| Transcriptome-Guided Identification of Drugs for Repurposing to Treat Age-Related Hearing Loss. | Schubert NMA et al. | β | 2022 | β |
| A deep learning framework for drug repurposing via emulating clinical trials on real-world patient data. | Liu R et al. | β | 2021 | β |
| Advancing drug discovery using the power of the human genome. | Heilbron K et al. | β | 2021 | β |
| Can Any Drug Be Repurposed for Cancer Treatment? A Systematic Assessment of the Scientific Literature. | Stransky N et al. | β | 2021 | β |
| DeepCOMBI: explainable artificial intelligence for the analysis and discovery in genome-wide association studies. | Mieth B et al. | β | 2021 | β |
| Drug Repurposing: Claiming the Full Benefit from Drug Development. | Kort E et al. | β | 2021 | β |
| Drug repurposing for COVID-19: Approaches, challenges and promising candidates. | Ng YL et al. | β | 2021 | β |
| Harnessing Drug Repurposing for Exploration of New Diseases: An Insight to Strategies and Case Studies. | Jain P et al. | β | 2021 | β |
| Identifying Novel Drug Targets by iDTPnd: A Case Study of Kinase Inhibitors. | Naveed H et al. | β | 2021 | β |
| Mendelian randomization for studying the effects of perturbing drug targets. | Gill D et al. | β | 2021 | β |
| Modeling regulatory network topology improves genome-wide analyses of complex human traits. | Zhu X et al. | β | 2021 | β |
| Predicting therapeutic drugs for hepatocellular carcinoma based on tissue-specific pathways. | Yu L et al. | β | 2021 | β |
| Repurposing of drugs: An attractive pharmacological strategy for cancer therapeutics. | Kirtonia A et al. | β | 2021 | β |
| Signature-based approaches for informed drug repurposing: targeting CNS disorders. | Shukla R et al. | β | 2021 | β |
| Systematic <i>in silico</i> Evaluation of <i>Leishmania</i> spp. Proteomes for Drug Discovery. | Dos Santos Vasconcelos CR et al. | β | 2021 | β |
| Systems Biology Approaches to Decipher the Underlying Molecular Mechanisms of Glioblastoma Multiforme. | Kaynar A et al. | β | 2021 | β |
| The complexity of Alzheimer's disease: an evolving puzzle. | Ferrari C et al. | β | 2021 | β |
| The Interface of Therapeutics and Genomics in Cardiovascular Medicine. | Magavern EF et al. | β | 2021 | β |
| The tumor therapy landscape of synthetic lethality. | Zhang B et al. | β | 2021 | β |
| Twelve years of GWAS discoveries for osteoporosis and related traits: advances, challenges and applications. | Zhu X et al. | β | 2021 | β |
| Using common genetic variants to find drugs for common epilepsies. | Mirza N et al. | β | 2021 | β |
| Using Human Genetics to Understand Mechanisms in Ischemic Stroke Outcome: From Early Brain Injury to Long-Term Recovery. | Lee JM et al. | β | 2021 | β |
| Web-based Tools for Drug Repurposing: Successful Examples of Collaborative Research. | Vanhaelen Q | β | 2021 | β |
| A common polymorphism in the retinoic acid pathway modifies adrenocortical carcinoma age-dependent incidence. | Surakhy M et al. | β | 2020 | β |
| A review of computational drug repositioning: strategies, approaches, opportunities, challenges, and directions. | Jarada TN et al. | β | 2020 | β |
| Current Status of COVID-19 Therapies and Drug Repositioning Applications. | Altay O et al. | β | 2020 | β |
| Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak. | Low ZY et al. | β | 2020 | β |
| Epidrug Repurposing: Discovering New Faces of Old Acquaintances in Cancer Therapy. | Montalvo-Casimiro M et al. | β | 2020 | β |
| Fluctuations of consciousness, mood, and science: The interhemispheric switch and sticky switch models two decades on. | Miller SM | β | 2020 | β |
| From genome-wide association studies to rational drug target prioritisation in inflammatory arthritis. | Fang H et al. | β | 2020 | β |
| Genome-wide pathogenesis interpretation using a heat diffusion-based systems genetics method and implications for gene function annotation. | Quan Y et al. | β | 2020 | β |
| Genomic Medicine: Lessons Learned From Monogenic and Complex Bone Disorders. | Trajanoska K et al. | β | 2020 | β |
| Has Drug Repurposing Fulfilled its Promise in Acute Myeloid Leukaemia? | Valli D et al. | β | 2020 | β |
| Identifying cross-disease components of genetic risk across hospital data in the UK Biobank. | Cortes A et al. | β | 2020 | β |
| Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases. | Zheng J et al. | β | 2020 | β |
| Predicting The Effects of Chemical-Protein Interactions On Proteins Using Tensor Factorisation. | Mohamed SK et al. | β | 2020 | β |
| PS4DR: a multimodal workflow for identification and prioritization of drugs based on pathway signatures. | Emon MA et al. | β | 2020 | β |
| Reaching the End-Game for GWAS: Machine Learning Approaches for the Prioritization of Complex Disease Loci. | Nicholls HL et al. | β | 2020 | β |
| Repurposing of medications for pulmonary arterial hypertension. | Toshner M et al. | β | 2020 | β |
| The Musculoskeletal Knowledge Portal: Making Omics Data Useful to the Broader Scientific Community. | Kiel DP et al. | β | 2020 | β |
| The support of genetic evidence for cardiovascular risk induced by antineoplastic drugs. | Cui H et al. | β | 2020 | β |
| Toward heterogeneous information fusion: bipartite graph convolutional networks for in silico drug repurposing. | Wang Z et al. | β | 2020 | β |
| Turning genome-wide association study findings into opportunities for drug repositioning. | Lau A et al. | β | 2020 | β |
| Understanding Drug Repurposing From the Perspective of Biomedical Entities and Their Evolution: Bibliographic Research Using Aspirin. | Li X et al. | β | 2020 | β |
| A network-based approach to identify deregulated pathways and drug effects in metabolic syndrome. | Misselbeck K et al. | β | 2019 | β |
| An update on Drug Repurposing: Re-written saga of the drug's fate. | Gns HS et al. | β | 2019 | β |
| Binding site matching in rational drug design: algorithms and applications. | Naderi M et al. | β | 2019 | β |
| Computational Drug Repurposing: Current Trends. | Karaman B et al. | β | 2019 | β |
| Concepts of Artificial Intelligence for Computer-Assisted Drug Discovery. | Yang X et al. | β | 2019 | β |
| Drug repositioning in pulmonary arterial hypertension: challenges and opportunities. | Grinnan D et al. | β | 2019 | β |
| Drug Repurposing Prediction for Immune-Mediated Cutaneous Diseases using a Word-Embedding-Based Machine Learning Approach. | Patrick MT et al. | β | 2019 | β |
| Drug repurposing: progress, challenges and recommendations. | Pushpakom S et al. | β | 2019 | β |
| Genetic Insights for Drug Development in NAFLD. | Eslam M et al. | β | 2019 | β |
| Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations. | Sakornsakolpat P et al. | β | 2019 | β |
| Genetic Support for Longevity-Enhancing Drug Targets: Issues, Preliminary Data, and Future Directions. | McCorrison J et al. | β | 2019 | β |
| Integration of target discovery, drug discovery and drug delivery: A review on computational strategies. | Duarte Y et al. | β | 2019 | β |
| Interactome Analyses implicated CAMK2A in the genetic predisposition and pharmacological mechanism of Bipolar Disorder. | Li H et al. | β | 2019 | β |
| Pathway analysis of GWAS loci identifies novel drug targets and repurposing opportunities. | Jhamb D et al. | β | 2019 | β |
| Pharmacogenomic Approach to Antimyopia Drug Development: Pathways Lead the Way. | Tkatchenko TV et al. | β | 2019 | β |
| Pharmacogenomics. | Roden DM et al. | β | 2019 | β |
| PheWAS-Based Systems Genetics Methods for Anti-Breast Cancer Drug Discovery. | Gao M et al. | β | 2019 | β |
| Precision drug repurposing via convergent eQTL-based molecules and pathway targeting independent disease-associated polymorphisms. | Vitali F et al. | β | 2019 | β |
| Predicting drug-target interaction network using deep learning model. | You J et al. | β | 2019 | β |
| Prioritizing target-disease associations with novel safety and efficacy scoring methods. | Failli M et al. | β | 2019 | β |
| Serendipity-A Machine-Learning Application for Mining Serendipitous Drug Usage From Social Media. | Ru B et al. | β | 2019 | β |
| Systematic analysis of genes and diseases using PheWAS-Associated networks. | Khosravi A et al. | β | 2019 | β |
| Systems Chemical Genetics-Based Drug Discovery: Prioritizing Agents Targeting Multiple/Reliable Disease-Associated Genes as Drug Candidates. | Quan Y et al. | β | 2019 | β |
| Translating GWAS findings into therapies for depression and anxiety disorders: gene-set analyses reveal enrichment of psychiatric drug classes and implications for drug repositioning. | So HC et al. | β | 2019 | β |
| Translational medicine in the Age of Big Data. | Tatonetti NP | β | 2019 | β |
| Use of big data in drug development for precision medicine: an update. | Qian T et al. | β | 2019 | β |
| Approaches and advances in the genetic causes of autoimmune disease and their implications. | Inshaw JRJ et al. | β | 2018 | β |
| Challenges and opportunities in stroke genetics. | Malik R et al. | β | 2018 | β |
| Computational drug repositioning for rare diseases in the era of precision medicine. | Delavan B et al. | β | 2018 | β |
| Connecting genetics and gene expression data for target prioritisation and drug repositioning. | Ferrero E et al. | β | 2018 | β |
| Druggability of Coronary Artery Disease Risk Loci. | Tragante V et al. | β | 2018 | β |
| Drug repurposing from the perspective of pharmaceutical companies. | Cha Y et al. | β | 2018 | β |
| Evolutionary and genetic features of drug targets. | Quan Y et al. | β | 2018 | β |
| Facilitating Anti-Cancer Combinatorial Drug Discovery by Targeting Epistatic Disease Genes. | Quan Y et al. | β | 2018 | β |
| Genome-wide and Phenome-wide Approaches to Understand Variable Drug Actions in Electronic Health Records. | Robinson JR et al. | β | 2018 | β |
| Identification of potential anti-hepatitis C virus agents targeting non structural protein 5B using computational techniques. | Polamreddy P et al. | β | 2018 | β |
| Leveraging multiple gene networks to prioritize GWAS candidate genes via network representation learning. | Wu M et al. | β | 2018 | β |
| Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. | Malik R et al. | β | 2018 | β |
| Opportunities and Challenges in Cardiovascular Pharmacogenomics: From Discovery to Implementation. | Roden DM et al. | β | 2018 | β |
| Post-GWAS in Psychiatric Genetics: A Developmental Perspective on the "Other" Next Steps. | Dick DM et al. | β | 2018 | β |
| Rare Diseases: Drug Discovery and Informatics Resource. | Zhao M et al. | β | 2018 | β |
| Repurposing sertraline sensitizes non-small cell lung cancer cells to erlotinib by inducing autophagy. | Jiang X et al. | β | 2018 | β |
| Re-thinking Alzheimer's disease therapeutic targets using gene-based tests. | Kwok MK et al. | β | 2018 | β |
| Revisiting Antipsychotic Drug Actions Through Gene Networks Associated With Schizophrenia. | Kauppi K et al. | β | 2018 | β |
| Systematic analyses of drugs and disease indications in RepurposeDB reveal pharmacological, biological and epidemiological factors influencing drug repositioning. | Shameer K et al. | β | 2018 | β |
| The Influence of Big (Clinical) Data and Genomics on Precision Medicine and Drug Development. | Denny JC et al. | β | 2018 | β |
| Varicose Veins Reach New Heights. | Wells QS | β | 2018 | β |
| Analysis of genome-wide association data highlights candidates for drug repositioning in psychiatry. | So HC et al. | β | 2017 | β |
| Bayesian analysis of genetic association across tree-structured routine healthcare data in the UK Biobank. | Cortes A et al. | β | 2017 | β |
| Beyond disease susceptibility-Leveraging genome-wide association studies for new insights into complex disease biology. | Lee JC | β | 2017 | β |
| Design of efficient computational workflows for in silico drug repurposing. | Vanhaelen Q et al. | β | 2017 | β |
| Drug enrichment and discovery from schizophrenia genome-wide association results: an analysis and visualisation approach. | Gaspar HA et al. | β | 2017 | β |
| Drug repositioning based on triangularly balanced structure for tissue-specific diseases in incomplete interactome. | Yu L et al. | β | 2017 | β |
| Drug repositioning for enzyme modulator based on human metabolite-likeness. | Lee YH et al. | β | 2017 | β |
| Drug repositioning for prostate cancer: using a data-driven approach to gain new insights. | Wang Q et al. | β | 2017 | β |
| Future Directions of Genomics Research in Rheumatic Diseases. | Okada Y et al. | β | 2017 | β |
| Genetic studies of alcohol dependence in the context of the addiction cycle. | Reilly MT et al. | β | 2017 | β |
| Genome-wide association analyses for lung function and chronic obstructive pulmonary disease identify new loci and potential druggable targets. | Wain LV et al. | β | 2017 | β |
| Genome-wide association studies of cancer: current insights and future perspectives. | Sud A et al. | β | 2017 | β |
| Human genetics as a model for target validation: finding new therapies for diabetes. | Thomsen SK et al. | β | 2017 | β |
| Leveraging human genetics to guide drug target discovery. | Stitziel NO et al. | β | 2017 | β |
| Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities. | Walker VM et al. | β | 2017 | β |
| Omics studies: their use in diagnosis and reclassification of SLE and other systemic autoimmune diseases. | Teruel M et al. | β | 2017 | β |
| Open Targets: a platform for therapeutic target identification and validation. | Koscielny G et al. | β | 2017 | β |
| Schizophrenia genetics comes to translation. | Domenici E | β | 2017 | β |
| Shared genetic origin of asthma, hay fever and eczema elucidates allergic disease biology. | Ferreira MA et al. | β | 2017 | β |
| Systematic integration of biomedical knowledge prioritizes drugs for repurposing. | Himmelstein DS et al. | β | 2017 | β |
| The druggable genome and support for target identification and validation in drug development. | Finan C et al. | β | 2017 | β |
| The Genetics of Ischemic Heart Disease: From Current Knowledge to Clinical Implications. | Elosua R et al. | β | 2017 | β |
| Uncovering novel repositioning opportunities using the Open Targets platform. | Khaladkar M et al. | β | 2017 | β |
| Advances in the genetics of schizophrenia: toward a network and pathway view for drug discovery. | Collier DA et al. | β | 2016 | β |
| A genomics-based systems approach towards drug repositioning for rheumatoid arthritis. | Xu R et al. | β | 2016 | β |
| An Integrated Data Driven Approach to Drug Repositioning Using Gene-Disease Associations. | Mullen J et al. | β | 2016 | β |
| A survey of current trends in computational drug repositioning. | Li J et al. | β | 2016 | β |
| Drug Repositioning for Alzheimer's Disease Based on Systematic 'omics' Data Mining. | Zhang M et al. | β | 2016 | β |
| Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System. | Regan K et al. | β | 2016 | β |
| Expanding the Immunology Toolbox: Embracing Public-Data Reuse and Crowdsourcing. | Sparks R et al. | β | 2016 | β |
| Explore Small Molecule-induced Genome-wide Transcriptional Profiles for Novel Inflammatory Bowel Disease Drug. | Cai X et al. | β | 2016 | β |
| Gene-set analysis based on the pharmacological profiles of drugs to identify repurposing opportunities in schizophrenia. | de Jong S et al. | β | 2016 | β |
| Genetic Association-Guided Analysis of Gene Networks for the Study of Complex Traits. | Greene CS et al. | β | 2016 | β |
| Meta-Analyses of Genome-Wide Association Data Hold New Promise for Addiction Genetics. | Agrawal A et al. | β | 2016 | β |
| Metabolomics enables precision medicine: "A White Paper, Community Perspective". | Beger RD et al. | β | 2016 | β |
| Mining integrated semantic networks for drug repositioning opportunities. | Mullen J et al. | β | 2016 | β |
| Pathway and network-based strategies to translate genetic discoveries into effective therapies. | Greene CS et al. | β | 2016 | β |
| Phenome-based gene discovery provides information about Parkinson's disease drug targets. | Chen Y et al. | β | 2016 | β |
| Phenome-Wide Association Studies as a Tool to Advance Precision Medicine. | Denny JC et al. | β | 2016 | β |
| Precision medicine, genomics and drug discovery. | Cardon LR et al. | β | 2016 | β |
| Precision medicine informatics. | Frey LJ et al. | β | 2016 | β |
| 'RE:fine drugs': an interactive dashboard to access drug repurposing opportunities. | Moosavinasab S et al. | β | 2016 | β |
| The case for genome-wide association studies of bone acquisition in paediatric and adolescent populations. | Kemp JP et al. | β | 2016 | β |
| Towards precision medicine-based therapies for glioblastoma: interrogating human disease genomics and mouse phenotypes. | Chen Y et al. | β | 2016 | β |
| Translating genome-wide association findings into new therapeutics for psychiatry. | Breen G et al. | β | 2016 | β |
| Using Social Media Data to Identify Potential Candidates for Drug Repurposing: A Feasibility Study. | Rastegar-Mojarad M et al. | β | 2016 | β |
| Vaccine Pipeline Has Grown During The Past Two Decades With More Early-Stage Trials From Small And Medium-Size Companies. | Hwang TJ et al. | β | 2016 | β |
| A comparative study of disease genes and drug targets in the human protein interactome. | Sun J et al. | β | 2015 | β |
| An integrated structure- and system-based framework to identify new targets of metabolites and known drugs. | Naveed H et al. | β | 2015 | β |
| A weighted and integrated drug-target interactome: drug repurposing for schizophrenia as a use case. | Huang LC et al. | β | 2015 | β |
| Combining Human Disease Genetics and Mouse Model Phenotypes towards Drug Repositioning for Parkinson's disease. | Chen Y et al. | β | 2015 | β |
| Computational systems biology approaches to anti-angiogenic cancer therapeutics. | Finley SD et al. | β | 2015 | β |
| Drug repositioning approaches for the discovery of new therapeutics for Alzheimer's disease. | Kim TW | β | 2015 | β |
| Drug repositioning for diabetes based on 'omics' data mining. | Zhang M et al. | β | 2015 | β |
| Failed drug discovery in psychiatry: time for human genome-guided solutions. | Papassotiropoulos A et al. | β | 2015 | β |
| Genetic architecture of colorectal cancer. | Peters U et al. | β | 2015 | β |
| Identification of drug candidates and repurposing opportunities through compound-target interaction networks. | Cichonska A et al. | β | 2015 | β |
| Identifying prognostic features by bottom-up approach and correlating to drug repositioning. | Li W et al. | β | 2015 | β |
| Identifying the biological basis of GWAS hits for endometriosis. | Fung JN et al. | β | 2015 | β |
| Mendelian Randomization: New Applications in the Coming Age of Hypothesis-Free Causality. | Evans DM et al. | β | 2015 | β |
| Mining drug-disease relationships as a complement to medical genetics-based drug repositioning: Where a recommendation system meets genome-wide association studies. | Wang H et al. | β | 2015 | β |
| Opportunities for drug repositioning from phenome-wide association studies. | Rastegar-Mojarad M et al. | β | 2015 | β |
| Protein localization vector propagation: a method for improving the accuracy of drug repositioning. | Yeu Y et al. | β | 2015 | β |
| Recent genetic findings in schizophrenia and their therapeutic relevance. | Harrison PJ | β | 2015 | β |
| Repurposing paclitaxel for the treatment of fibrosis: indication discovery for existing drugs. | Chen XW et al. | β | 2015 | β |
| Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic. | Lencz T et al. | β | 2015 | β |
| The support of human genetic evidence for approved drug indications. | Nelson MR et al. | β | 2015 | β |
| TYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traits. | Diogo D et al. | β | 2015 | β |
| Use of genome-wide association studies for cancer research and drug repositioning. | Zhang J et al. | β | 2015 | β |
| Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality. | Xu H et al. | β | 2015 | β |
| Allelic expression mapping across cellular lineages to establish impact of non-coding SNPs. | Adoue V et al. | β | 2014 | β |
| An atlas of genetic influences on human blood metabolites. | Shin SY et al. | β | 2014 | β |
| A network perspective on unraveling the role of TRP channels in biology and disease. | Chun JN et al. | β | 2014 | β |
| Approaches for establishing the function of regulatory genetic variants involved in disease. | Knight JC | β | 2014 | β |
| Construction of drug network based on side effects and its application for drug repositioning. | Ye H et al. | β | 2014 | β |
| DiseaseConnect: a comprehensive web server for mechanism-based disease-disease connections. | Liu CC et al. | β | 2014 | β |
| Extraintestinal manifestations and complications in inflammatory bowel disease: from shared genetics to shared biological pathways. | van Sommeren S et al. | β | 2014 | β |
| From the era of genome analysis to the era of genomic drug discovery: a pioneering example of rheumatoid arthritis. | Okada Y | β | 2014 | β |
| Genetic Discoveries in Atrial Fibrillation and Implications for Clinical Practice. | Mahida S | β | 2014 | β |
| Genetics, ancestry, and hypertension: implications for targeted antihypertensive therapies. | Franceschini N et al. | β | 2014 | β |
| Genetics of rheumatoid arthritis contributes to biology and drug discovery. | Okada Y et al. | β | 2014 | β |
| GWAS and drug targets. | Cao C et al. | β | 2014 | β |
| How will insights from genetics translate to clinical practice in inflammatory bowel disease? | Festen EA et al. | β | 2014 | β |
| Identification of novel therapeutics for complex diseases from genome-wide association data. | Grover MP et al. | β | 2014 | β |
| Integrative clinical transcriptomics analyses for new therapeutic intervention strategies: a psoriasis case study. | Qu XA et al. | β | 2014 | β |
| Large-scale genomics unveils the genetic architecture of psychiatric disorders. | Gratten J et al. | β | 2014 | β |
| Medical genetic inspirations for anticancer drug repurposing. | Wang ZY et al. | β | 2014 | β |
| Mouse model phenotypes provide information about human drug targets. | Hoehndorf R et al. | β | 2014 | β |
| [Personalized medicine: equity and access]. | Joly Y et al. | β | 2014 | β |
| Predicting disease associations via biological network analysis. | Sun K et al. | β | 2014 | β |
| Research review: Polygenic methods and their application to psychiatric traits. | Wray NR et al. | β | 2014 | β |
| [Role of bioinformatics in research and development of antipsychotic agents]. | Kuwahara Y et al. | β | 2014 | β |
| Surveying Recent Themes in Translational Bioinformatics: Big Data in EHRs, Omics for Drugs, and Personal Genomics. | Denny JC | β | 2014 | β |
| The future for genetic studies in reproduction. | Montgomery GW et al. | β | 2014 | β |
| The genome revolution and its role in understanding complex diseases. | Hofker MH et al. | β | 2014 | β |
| The integrated disease network. | Sun K et al. | β | 2014 | β |
| Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. | Jin G et al. | β | 2014 | β |
| Towards drug repositioning: a unified computational framework for integrating multiple aspects of drug similarity and disease similarity. | Zhang P et al. | β | 2014 | β |
| [Use of GWAS for drug discovery and development]. | Liou SY | β | 2014 | β |
| Using VisANT to Analyze Networks. | Hu Z | β | 2014 | β |
| Beyond GWASs: illuminating the dark road from association to function. | Edwards SL et al. | β | 2013 | β |
| Compensating for literature annotation bias when predicting novel drug-disease relationships through Medical Subject Heading Over-representation Profile (MeSHOP) similarity. | Cheung WA et al. | β | 2013 | β |
| Computational drug repositioning: from data to therapeutics. | Hurle MR et al. | β | 2013 | β |
| Drug interaction networks: an introduction to translational and clinical applications. | Azuaje F | β | 2013 | β |
| Drug Promiscuity in PDB: Protein Binding Site Similarity Is Key. | Haupt VJ et al. | β | 2013 | β |
| Drug repositioning: a machine-learning approach through data integration. | Napolitano F et al. | β | 2013 | β |
| Drug repositioning for orphan genetic diseases through Conserved Anticoexpressed Gene Clusters (CAGCs). | Molineris I et al. | β | 2013 | β |
| Gene-expression data integration to squamous cell lung cancer subtypes reveals drug sensitivity. | Wu D et al. | β | 2013 | β |
| Genetic architecture of quantitative traits and complex diseases. | Fu W et al. | β | 2013 | β |
| Genomic medicine: a decade of successes, challenges, and opportunities. | McCarthy JJ et al. | β | 2013 | β |
| Genomic modulators of the immune response. | Knight JC | β | 2013 | β |
| Human genetics in rheumatoid arthritis guides a high-throughput drug screen of the CD40 signaling pathway. | Li G et al. | β | 2013 | β |
| Human genome-guided identification of memory-modulating drugs. | Papassotiropoulos A et al. | β | 2013 | β |
| Neuroimaging as a potential biomarker to optimize psychiatric research and treatment. | Walton E et al. | β | 2013 | β |
| Objective assessment of cancer genes for drug discovery. | Patel MN et al. | β | 2013 | β |
| Progress and future aspects in genetics of human hypertension. | Zhao Q et al. | β | 2013 | β |
| Rational drug repositioning by medical genetics. | Wang ZY et al. | β | 2013 | β |
| Reply to Rational drug repositioning by medical genetics. | Sanseau P et al. | β | 2013 | β |
| Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review. | Csermely P et al. | β | 2013 | β |
| TargetHunter: an in silico target identification tool for predicting therapeutic potential of small organic molecules based on chemogenomic database. | Wang L et al. | β | 2013 | β |
| Transcriptional data: a new gateway to drug repositioning? | Iorio F et al. | β | 2013 | β |
| VisANT 4.0: Integrative network platform to connect genes, drugs, diseases and therapies. | Hu Z et al. | β | 2013 | β |
| Applications of Connectivity Map in drug discovery and development. | Qu XA et al. | β | 2012 | β |
| Network analysis has diverse roles in drug discovery. | Hasan S et al. | β | 2012 | β |
| The serotonin transporter gene and depression. | MunafΓ² MR | β | 2012 | β |